SE9303612D0 - New use - Google Patents

New use

Info

Publication number
SE9303612D0
SE9303612D0 SE9303612A SE9303612A SE9303612D0 SE 9303612 D0 SE9303612 D0 SE 9303612D0 SE 9303612 A SE9303612 A SE 9303612A SE 9303612 A SE9303612 A SE 9303612A SE 9303612 D0 SE9303612 D0 SE 9303612D0
Authority
SE
Sweden
Prior art keywords
medicament
pla2
heparin
phospholipases
low
Prior art date
Application number
SE9303612A
Other languages
English (en)
Inventor
Lars Aa Hanson
Andrej Tarkowski
Bruno Lomonte
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9303612A priority Critical patent/SE9303612D0/sv
Publication of SE9303612D0 publication Critical patent/SE9303612D0/sv
Priority to AU81195/94A priority patent/AU8119594A/en
Priority to PCT/SE1994/001030 priority patent/WO1995012403A1/en

Links

SE9303612A 1993-11-02 1993-11-02 New use SE9303612D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9303612A SE9303612D0 (sv) 1993-11-02 1993-11-02 New use
AU81195/94A AU8119594A (en) 1993-11-02 1994-11-02 Use of low anticoagulant heparinderivatives
PCT/SE1994/001030 WO1995012403A1 (en) 1993-11-02 1994-11-02 Use of low anticoagulant heparinderivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303612A SE9303612D0 (sv) 1993-11-02 1993-11-02 New use

Publications (1)

Publication Number Publication Date
SE9303612D0 true SE9303612D0 (sv) 1993-11-02

Family

ID=20391615

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9303612A SE9303612D0 (sv) 1993-11-02 1993-11-02 New use

Country Status (3)

Country Link
AU (1) AU8119594A (sv)
SE (1) SE9303612D0 (sv)
WO (1) WO1995012403A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
MX2020009877A (es) * 2018-03-27 2021-01-08 Brian Lohse Péptidos neutralizantes de miotoxina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases

Also Published As

Publication number Publication date
AU8119594A (en) 1995-05-23
WO1995012403A1 (en) 1995-05-11

Similar Documents

Publication Publication Date Title
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE69108048T2 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
DE69526120T2 (de) Verwendung von nebivolol als anti-atherogenisches mittel
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
DE69710065D1 (de) Androsten-derivate
DE69731610D1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
EA200500804A1 (ru) Топические противоинфекционные композиции
SE9602931L (sv) Ny medicinsk användning
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
DK1167354T3 (da) Racemisk huperzin A
PT888327E (pt) Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BRPI0414887A (pt) métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
SE9303612D0 (sv) New use
DE69705110T2 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
NO20003510D0 (no) Fett-bindende polymerer
NO990450L (no) Behandling av sinnslidelser
DE69103773T2 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
PT1058544E (pt) Inibicao da actividade do tnf
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására